Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Abbott India Limited

NSE: ABBOTINDIAPharmaceuticals

Share price

₹25,580.00

-1.97% close of 8 Oct 2026

Market cap ₹53,718 CrP/E 33.3

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

68

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹53,718 Cr

P/E ratio

33.3

P/B ratio

11.4

ROCE

44.8%

ROE

34.5%

Dividend yield

2.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹30,255.0052-week low ₹25,180.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 6.3% over the past year, and 14.9% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 21.8% to 28.1% over the last four years.

Whether it grew faster than its sector

It grew 14.9% a year against a sector median of 13.1% — 1.8 percentage points faster.

Room to re-rate, or risk of de-rating

At 33.3× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 49.5×, the 0th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.8 times its growth rate, on earnings growth of 18%.

Profit growthPrice per ₹1 profitPer 1% growth
Abbott India Limited — this one18%/yr33.3×₹1.8
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 6 of 130 on returns, 42 of 127 on growth, 35 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 44.8% on capital, ahead of 95% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹5385 crore of cash from the business, spent ₹189 crore on plant and equipment, and returned ₹4012 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 93 arrived as cash. Its cash comes back more slowly than it used to: it went from being paid 7 days before it paid its own suppliers to waiting 2 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 8 checks clear · 100%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue was Rs 1813.68 crore with profit of Rs 428.52 crore.

Announced 12 Aug 2026 · Standalone · Unaudited

Revenue

₹1,814 Cr

Revenue vs last year

+4.3%

Revenue vs last quarter

+6.1%

Net profit

₹429 Cr

Profit vs last year

+17.1%

Profit vs last quarter

+8.5%

Net margin

23.6%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹53,718 Cr
Prev close
₹25,580.00
52w High
₹30,655
52w Low
₹25,135
Enterprise value
₹54,500 Cr
Beta
0.3
Price CAGR 1y
-13.0%
Price CAGR 3y
4.0%
Price CAGR 5y
4.0%
Price CAGR 10y
19.0%

Ratios

Return on assets
23.9%
PEG ratio
1.9
P/E ratio
33.3
P/B ratio
11.4
EV / EBITDA
28.8
Industry P/E
38.0
ROCE
44.8%
ROCE 5y average
43.2%
ROE
34.5%
Debt / Equity
0.0
Interest coverage
84.2
Dividend yield
2.0%
ROE 3y average
35.0%
ROE last year
34.0%

Annual P&L

Annual revenue
₹6,929 Cr
Annual profit
₹1,552 Cr
Operating margin
27.0%
Net profit margin
22.4%
EBITDA margin
27.3%
Sales growth 3y
9.0%
Sales growth 5y
10.0%
Profit growth 3y
18.0%
Profit growth 5y
17.0%
EPS
₹730
Sales growth TTM
6.0%
Profit growth TTM
11.0%
Dividend payout
90.0%

Quarter P&L

Sales latest quarter
₹1,814 Cr
Profit latest quarter
₹429 Cr
YoY quarterly sales growth
4.3%
YoY quarterly profit growth
17.2%
OPM latest quarter
28.8%

Balance Sheet

Book Value
₹2,273
Face Value
₹10.0
Total debt
₹172 Cr
Total cash
₹2,232 Cr
Borrowings
₹172 Cr
Reserves / Equity
226.3

Cash Flow

Operating cash flow
₹1,319 Cr
Free cash flow
₹1,307 Cr
FCF yield
2.4%
Net cash flow
-₹118 Cr

Shareholding

Promoter holding
75.0%
FII holding
0.4%
DII holding
8.8%
Public holding
15.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Abbott India26,095.0034.355,4222.01428.517.11,813.74.344.8
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,4791,4941,4371,4391,5581,6331,6141,6051,7381,7571,7241,7101,814
Expenses1,1241,1131,0491,1091,1671,1941,1781,1761,2931,2551,2611,2291,291
Material Cost151
Change in Inventories-31
Purchases of Stock-in-Trade812
Employee Cost175
Other Expenses184
Operating Profit355381388330391439436429446502463481522
OPM %24252723252727272629272829
Other Income56565681676072767370707675
Exceptional items (within Other Income)0
Interest3333322468566
Depreciation17181818181818181919191920
Profit before tax390415422390437479488483493546509531572
Tax %26252626252526242624262625
Net Profit290313311287328359361367366415376395429
EPS in Rs137147146135154169170173172195177186202

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,2892,6142,9033,2983,6794,0934,3104,9195,3495,8496,4096,9297,004
Expenses1,9772,2502,5052,7743,0743,3363,3883,8324,1434,3964,7145,0375,035
Operating Profit3123653985256057579221,0881,2061,4531,6951,8921,969
OPM %14141416161821222325262728
Other Income4850571171131148177154248275288291
Interest03242918191612112525
Depreciation15141616176058667071727676
Profit before tax3443984366216998039261,0801,2741,6181,8872,0792,158
Tax %343637353626252625262525
Net Profit2292552774014505936917999491,2011,4141,5521,615
EPS in Rs108120130189212279325376447565666730760
Dividend Payout %292931293190857373737190

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
10%
5 years
10%
3 years
9%
TTM
6%

Compounded profit growth

10 years
20%
5 years
17%
3 years
18%
TTM
11%

Stock price CAGR

10 years
19%
5 years
4%
3 years
4%
1 year
-13%

Return on equity

10 years
31%
5 years
34%
3 years
35%
Last year
34%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital212121212121212121212121
Reserves9161,1741,3661,6721,9872,4102,5812,7993,1673,6784,2124,753
Borrowings0000017515315211383197172
Other Liabilities4364216797239329401,0861,2531,2541,4111,4871,556
Total Liabilities1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502
Fixed Assets9610811081105270251271237225336331
CWIP43621211410186
Investments000000000000
Other Assets1,2741,5051,9502,3332,8353,2753,5893,9524,3154,9585,5636,165
Total Assets1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity2152493071534996267279488931,2131,0121,319
Cash from Investing Activity-187-77-155-215-257-401-72-396-148-416182-371
Cash from Financing Activity-58-80-90-102-143-217-582-637-639-745-925-1,066
Net Cash Flow-309162-16599873-8610752269-118
Free Cash Flow1992262871805046117049048601,1659601,307

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days212022292728212122202219
Inventory Days10791107112106831109480709294
Days Payable545610192116104116122109114110109
Cash Conversion Cycle7454284917814-6-8-2433
Working Capital Days3032216322104-7-8-14992
ROCE %403834413735353841464645

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters757575757575757575757575
FIIs0.190.180.180.180.170.170.160.160.160.190.270.38
DIIs8.838.738.918.8199.018.919.189.1198.938.77
Public161616161616161616161616
No. of Shareholders68,88572,25269,38271,58869,44967,89269,93467,58471,19975,80175,86678,320

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -13.8% (₹29,690.00 → ₹25,580.00)Brick size ₹603.36 (fixed)Bricks 22
₹28,000₹25,580Dec '25Apr '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹25,580.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

News

News and filings about Abbott India Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients (APIs)
  • Finished formulations / stock-in-trade from Abbott affiliates
  • Pharmaceutical packaging materials

Products sold by

Buys drug ingredients from

  • Abbott Laboratories (global affiliates)

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE358A01014

Plants

  • Abbott India Baddi manufacturing facility · Baddi, Himachal Pradesh
  • Abbott India Goa manufacturing facility · Goa, Goa

News impact

Big market events that reach Abbott India Limited, and how the effect spreads.

Who it hits first

  • Nestle India's baby-milk powders NAN Excella Pro and Lactogen Pro face FSSAI legal action over ad claims, plus one sample that fell short on Biotin — expect the company to pull or rewrite claims, change pack labels, and sit through weeks of negative headlines.
  • No ban or recall has been ordered, so the hit is reputation and legal cost rather than lost sales; infant formula is only one small part of Nestle India's business behind Maggi noodles, dairy and chocolate.

Who may gain

  • Abbott India, whose Similac baby formula sits on the same chemist shelves as NAN and Lactogen, may win a few trial-switching parents over the next month or two.
  • No other listed company gains meaningfully — broad foods peers like ITC, Hindustan Unilever and Britannia sell no baby formula.

Along the supply chain

Downstream

Chemists, pharmacies and distributors may briefly tilt baby-formula shelf facings and recommendations toward Similac while Nestle headlines run hot.

Upstream

Suppliers of milk solids, packaging and ingredients feeding two baby-formula product lines see effectively no volume change, since production continues and only labels and ads are in question.

Where demand moves

Business

A small share of new parents may switch baby-milk brands from NAN or Lactogen to Similac on pediatrician advice over 1-2 months, but formula buying is sticky and doctor-led, so volumes move slowly and rivals gain only at the margin.

Capital

No sector-wide money rotation is expected: packaged-food shares stay in their defensive bucket, and any Nestle dip is a stock-specific wobble that bargain hunters, not sector sellers, will trade.

How it spreads across sectors

Fast Moving Consumer Goods

FSSAI scrutiny of functional nutrition claims such as HMOs and whey protein sets a precedent that could extend to health drinks and supplements, a mild overhang for claim-heavy brands like Horlicks, Boost and Complan.

Healthcare

Abbott India marginally positive via Similac trial-switching; no wider hospital or pharma read-through.

Commodity angle

Cc skip reason

no_commodity_link

When it plays out

Immediate

In the next few days Nestle shares likely dip 1-3% on sentiment while peers stay flat; watch for the company's first response.

Medium term

Over 1-6 months a fine or settlement and new labels should close the matter with limited lasting effect on earnings, given the small sales share at stake.

Short term

Over 1-4 weeks expect claim withdrawals, label-change plans and clarity on the legal process; the news cycle decides the depth of the dip.

Who it hits first

  • Manufacturers of the 16 banned FDC formulations — primarily mid-tier OTC/branded acute players (cold/cough/analgesic combos)
  • Most listed names: <1% revenue exposure individually

Who may gain

  • Single-molecule branded pharma (ABBOTINDIA, GSK PHARMA, PFIZER) — prescription rotation potential
  • MNC pharma with cleaner portfolios

Along the supply chain

Downstream

Pharmacy retailers (APOLLOHOSP, MEDPLUS, NETMEDS) face brief inventory rebalancing; minimal revenue impact.

Upstream

Active Pharmaceutical Ingredient (API) suppliers for the banned combos see minor demand reduction — limited impact as same APIs are used in single-molecule formulations.

Where demand moves

Business

FDC ban removes ~16 specific formulations from market — prescribers switch to single-molecule alternatives or non-banned FDCs; net demand displacement, not destruction.

Capital

Sentiment-driven mild sell-off in OTC-heavy names (MANKIND, CIPLA); rotation into MNC-style branded pharma (ABBOTINDIA, GSKPH).

How it spreads across sectors

Healthcare

Modest negative for FDC-heavy MNCs; positive for single-molecule MNCs

Pharma

Mild negative for OTC/branded-acute heavy players; neutral for specialty/US-generics focused

When it plays out

Immediate

Monday open: mild selling pressure on MANKIND, CIPLA — likely -1-2% as market gauges actual exposure

Medium term

Pattern of FDC bans accelerating — sector earnings models stress higher recurring regulatory cost

Short term

Pharma companies issue impact statements; specific FDC contribution to revenue clarified

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

24 Jul 2026unspecified₹525
24 Jul 2026special₹131
25 Jul 2025unspecified₹475
19 Jul 2024unspecified₹410
21 Jul 2023unspecified₹180
21 Jul 2023special₹145
2 Aug 2022unspecified₹145
19 Jul 2021unspecified₹120

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.